ArriVent BioPharma, Inc. (AVBP) vs Inhibrx Biosciences, Inc. (INBX)

ArriVent BioPharma, Inc. and Inhibrx Biosciences, Inc. are both Biotechnology companies. ArriVent BioPharma, Inc. and Inhibrx Biosciences, Inc. are of similar size ($1.5B and $1.5B). Across the 8 metrics below, ArriVent BioPharma, Inc. leads on 4 and Inhibrx Biosciences, Inc. on 4.

Valuation

Metric AVBP INBX Biotechnology median
P/E n/m n/m 7.88
P/S n/m 495.33 11.47
P/B 3.69 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 508.96 10.73
Earnings yield (12.72%) (8.91%) (28.84%)
Free cash flow yield (10.92%) (8.45%) (23.03%)

Profitability

Metric AVBP INBX Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (53.10%) (1,773.60%) (57.72%)
Return on assets (49.30%) (75.44%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AVBP INBX Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) (68.75%) (108.03%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric AVBP INBX Biotechnology median
Debt to equity 0.00 (3.33) 0.00
Current ratio 14.16 5.07 4.73
Net debt to EBITDA 1.73 0.18 0.96

Dividend

Metric AVBP INBX Biotechnology median
Dividend yield — — 2.10%
Payout ratio — — 0.00

Size

Metric AVBP INBX Biotechnology median
Market cap 1.48b 1.48b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack